News — AI supercycle headlines

Zacks1d agobearish

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.

HIMS ^DJI ^GSPC

StockStory4d agobearish

1 Russell 2000 Stock Worth Your Attention and 2 That Underwhelm

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Simply Wall St.5d agobearish

Data Breach Lawsuits Test Hims And Hers Health Valuation And Momentum

Two class action lawsuits claim Hims & Hers Health did not adequately safeguard sensitive customer data during recent data breaches. The suits allege delayed notification to affected customers and increased risk of identity theft, and they seek damages plus stronger data security oversight. These cases introduce fresh legal and reputational questions for NYSE:HIMS that have not been widely covered so far. For investors watching NYSE:HIMS, this legal development adds a new angle to a stock...

HIMS

Barrons.com8d agobearish

Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.

A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patients with lung and pancreatic cancer. Investors quickly drew parallels to daraxonrasib, the high-profile lead asset from Revolution Medicines Daraxonrasib has been on the receiving end of a storm of media coverage following an endorsement from former Nebraska Sen. Ben Sasse.

HIMS